Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lantern Pharma Inc. (LTRN : NSDQ)

• Company Description    Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $6.00 Daily Weekly Monthly 20 Day Moving Average: 21,518 shares Shares Outstanding: 10.83 (millions) Market Capitalization: $64.99 (millions) Beta: 1.59 52 Week High: $16.50 52 Week Low: $5.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.30% -2.34% 12 Week -4.76% 4.71% Year To Date -24.81% -8.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1920 MCKINNEY AVENUE 7TH FLOOR - DALLAS,TX 75201 USA ph: 972-277-1136 fax: - ir@lanternpharma.com http://www.lanternpharma.com

• General Corporate Information    Officers Panna Sharma - Chief Executive Officer and President Donald J. Keyser - Chairman David R. Margrave - Chief Financial Officer Leslie W. Kreis - Director David S. Silberstein - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 51654W101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 10.83 Most Recent Split Date: (:1) Beta: 1.59 Market Capitalization: $64.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.94 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.99 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -58.33% vs. Previous Quarter: -22.58% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -19.12 12/31/21 - -15.97 09/30/21 - -18.25 ROA 03/31/22 - -18.48 12/31/21 - -15.57 09/30/21 - -17.83 Current Ratio 03/31/22 - 22.01 12/31/21 - 31.26 09/30/21 - 42.74 Quick Ratio 03/31/22 - 22.01 12/31/21 - 31.26 09/30/21 - 42.74 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.03 12/31/21 - 6.40 09/30/21 - 6.77 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©